Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Testing Diabetes Drug Dosage
Clinical Breakthroughs

Testing Diabetes Drug Dosage

By Sarah PlumridgeApr 15, 2016
Share
Facebook Twitter Email
Robert Kushner, MD
Robert Kushner, MD, ’80 ’82 GME, professor of Medicine in the Division of Endocrinology, was site principal investigator and co-author of a study that investigated the safety and efficacy of a type 2 diabetes drug used to help patients manage weight.

While weight loss is recommended for patients diagnosed with type 2 diabetes, lifestyle interventions alone can often be challenging because of obesity-related hormonal, metabolic and neuronal adaptations that favor weight gain.

A recent study investigated whether a higher dose of liraglutide, a drug used to treat type 2 diabetes, may lead to greater weight loss. The study, co-authored by Robert Kushner, MD, ’80 ’82 GME, professor of Medicine in the Division of Endocrinology, found encouraging results.

“Using a higher dose of liraglutide leads to significant weight loss, improvement in diabetes control and other metabolic parameters, and it improves the quality of life among individuals with type 2 diabetes and obesity,” said Dr. Kushner, who was principle investigator of the Northwestern site.

The 56-week randomized trial, published in the Journal of the American Medical Association (JAMA), was conducted at 126 sites in nine countries from 2011-2013. A total of 846 adult patients who were overweight or obese and diagnosed with diabetes were enrolled in the study and either received 3 milligrams of liraglutide, 1.8 milligrams or a placebo. Liraglutide binds to the same receptors as the metabolic hormone GLP-1 and stimulates insulin secretion.

The scientists found that weight loss was significantly greater at all dosages of liraglutide (3.0 mg and 1.8 mg) versus placebo. They also found significant reductions in waist circumference, body mass index, blood pressure and improved glycemic control. While the authors did not identify any new safety concerns, they suggested further studies are needed to evaluate longer-term efficacy and safety.

Next, Dr. Kushner said he is working on “implementation of improved obesity care among primary care providers with a refocus on the underlying problem – obesity, rather than simply focusing on improving blood sugar.”

Liraglutide is a proprietary compound of Novo Nordisk, the pharmaceutical company that funded the study. Dr. Kushner also reported serving on advisory boards for Novo Nordisk.

Endocrinology Research
Share. Facebook Twitter Email

Related Posts

Mapping Neural Activity Patterns and Odor Perception  

Sep 28, 2023

Small, Implantable Device Could Sense and Treat Cancer

Sep 26, 2023

Gene Linked to Glioblastoma Stem Cell Self-Renewal and Immunosuppression

Sep 26, 2023

Comments are closed.

Latest News

Medical Education Day Celebrates Mentorship and Equity

Sep 29, 2023

Mapping Neural Activity Patterns and Odor Perception  

Sep 28, 2023

Lloyd-Jones Announces He is Stepping Down as Chair of Preventive Medicine

Sep 27, 2023

Small, Implantable Device Could Sense and Treat Cancer

Sep 26, 2023

Gene Linked to Glioblastoma Stem Cell Self-Renewal and Immunosuppression

Sep 26, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230927_MedEdDay_Sargent_6
20230927_MedEdDay_Sargent_3
20230927_MedEdDay_Sargent_1
20230927_MedEdDay_Posters_Patel_2
20230927_MedEdDay_Posters_Patel_1
20230927_MedEdDay_Posters_Panko_1
20230927_MedEdDay_Posters_4
20230927_MedEdDay_Posters_3
20230927_MedEdDay_Posters_2
20230927_MedEdDay_Posters_1
20230927_MedEdDay_Awards_6
20230927_MedEdDay_Awards_5

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.